Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development ...

It's rightly said love overcomes everything and has the power to turn fate. Popular actor Sharib Hashmi, best known for ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK- Demand in April 2026 ...

Medical imaging routinely used in cancer care may hold far more biological information than previously thought.

Medical imaging routinely used in cancer care may hold far more biological information than previously thought. An ...

A research team led by the Medical University of Vienna has demonstrated in a recent study that the biological characteristics of a subgroup of head and neck tumors - which are very aggressive in many ...

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongo ...

Indian American scientist recognized for advancing understanding of tumor growth and treatment resistance in head and neck ...

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing ...

Scientists at the University of Pennsylvania are exploring a surprising new idea: chewing gum that could help target microbes ...